Literature DB >> 16990853

How will HPV vaccines affect cervical cancer?

Richard Roden1, T-C Wu.   

Abstract

Cancer of the uterine cervix is the second largest cause of cancer deaths in women, and its toll is greatest in populations that lack screening programmes to detect precursor lesions. Persistent infection with 'high risk' genotypes of human papillomavirus (HPV) is necessary, although not sufficient, to cause cervical carcinoma. Therefore, HPV vaccination provides an opportunity to profoundly affect cervical cancer incidence worldwide. A recently licensed HPV subunit vaccine protects women from a high proportion of precursor lesions of cervical carcinoma and most genital warts. Here we examine the ramifications and remaining questions that surround preventive HPV vaccines.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16990853      PMCID: PMC3181152          DOI: 10.1038/nrc1973

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  115 in total

1.  HPV6b virus like particles are potent immunogens without adjuvant in man.

Authors:  L F Zhang; J Zhou; S Chen; L L Cai; Q Y Bao; F Y Zheng; J Q Lu; J Padmanabha; K Hengst; K Malcolm; I H Frazer
Journal:  Vaccine       Date:  2000-01-06       Impact factor: 3.641

Review 2.  Public health paradoxes and the epidemiological impact of an HPV vaccine.

Authors:  G P Garnett; H C Waddell
Journal:  J Clin Virol       Date:  2000-10       Impact factor: 3.168

3.  Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod.

Authors:  Gerd Rechtsteiner; Tobias Warger; Philipp Osterloh; Hansjörg Schild; Markus P Radsak
Journal:  J Immunol       Date:  2005-03-01       Impact factor: 5.422

4.  Attempted transmission of warts from man, cattle, and horses and of deer fibroma, to selected hosts.

Authors:  L D Koller; C Olson
Journal:  J Invest Dermatol       Date:  1972-06       Impact factor: 8.551

5.  Characterization of a major neutralizing epitope on human papillomavirus type 16 L1.

Authors:  W I White; S D Wilson; F J Palmer-Hill; R M Woods; S J Ghim; L A Hewitt; D M Goldman; S J Burke; A B Jenson; S Koenig; J A Suzich
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

6.  In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype.

Authors:  R B Roden; H L Greenstone; R Kirnbauer; F P Booy; J Jessie; D R Lowy; J T Schiller
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

7.  Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies.

Authors:  R C Rose; W I White; M Li; J A Suzich; C Lane; R L Garcea
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

8.  Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera.

Authors:  R C Rose; R C Reichman; W Bonnez
Journal:  J Gen Virol       Date:  1994-08       Impact factor: 3.891

9.  Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus.

Authors:  N D Christensen; C A Reed; N M Cladel; R Han; J W Kreider
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

10.  Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1.

Authors:  David Baud; Françoise Ponci; Martine Bobst; Pierre De Grandi; Denise Nardelli-Haefliger
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

View more
  94 in total

Review 1.  Estrogen and ERalpha: culprits in cervical cancer?

Authors:  Sang-Hyuk Chung; Silvia Franceschi; Paul F Lambert
Journal:  Trends Endocrinol Metab       Date:  2010-04-22       Impact factor: 12.015

2.  Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection.

Authors:  Subhashini Jagu; Kihyuck Kwak; Robert L Garcea; Richard B S Roden
Journal:  Vaccine       Date:  2010-04-29       Impact factor: 3.641

3.  CCND1 G870A polymorphism and cervical cancer risk: a case-control study and meta-analysis.

Authors:  Jing Ni; Meilin Wang; Miaomiao Wang; Shilong Fu; Delan Zhou; Zhengdong Zhang; Suping Han
Journal:  J Cancer Res Clin Oncol       Date:  2010-05-15       Impact factor: 4.553

4.  Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2.

Authors:  Ratish Gambhira; Subhashini Jagu; Balasubramanyam Karanam; Patti E Gravitt; Timothy D Culp; Neil D Christensen; Richard B S Roden
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

5.  Inhibitory effects of dobutamine on human gastric adenocarcinoma.

Authors:  Hui-Xia Zheng; Li-Na Wu; Hong Xiao; Qian Du; Jian-Fang Liang
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

6.  Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment.

Authors:  Zhenhua Lin; Martina Bazzaro; Mei-Cheng Wang; Kwun C Chan; Shiwen Peng; Richard B S Roden
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

Review 7.  Papillomavirus prophylactic vaccines: established successes, new approaches.

Authors:  M Saveria Campo; Richard B S Roden
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

8.  Prevention and treatment of cervical cancer in mice using estrogen receptor antagonists.

Authors:  Sang-Hyuk Chung; Paul F Lambert
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-09       Impact factor: 11.205

9.  Human papillomavirus DNA detection in menstrual blood from patients with cervical intraepithelial neoplasia and condyloma acuminatum.

Authors:  Sze Chuen Cesar Wong; Thomas Chi Chuen Au; Sammy Chung Sum Chan; Charles Ming Lok Chan; Money Yan Yee Lam; Benny Chung Ying Zee; Wei Mei Pong; Anthony Tak Cheung Chan
Journal:  J Clin Microbiol       Date:  2010-01-20       Impact factor: 5.948

10.  Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine.

Authors:  Subhashini Jagu; Kihyuck Kwak; John T Schiller; Douglas R Lowy; Harold Kleanthous; Kirill Kalnin; Chenguang Wang; Hsu-Kun Wang; Louise T Chow; Warner K Huh; Kilvani S Jaganathan; Sudha V Chivukula; Richard B S Roden
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.